Acuta Capital Partners, LLC Merus N.V. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$18.64 - $28.93 $1.77 Million - $2.75 Million	-95,000 Reduced 61.69%	59,000 $1.18 Million
Q2 2022 Aug 15, 2022	SELL	$13.98 - $29.25 $1.14 Million - $2.38 Million	-81,500 Reduced 34.61%	154,000 $3.49 Million
Q4 2021 Feb 14, 2022	BUY	$20.0 - $32.29 $2.27 Million - $3.66 Million	113,500 Added 93.03%	235,500 $7.49 Million
Q3 2021 Nov 15, 2021	BUY	$16.48 - $27.23 $2.01 Million - $3.32 Million	122,000 New	122,000 $2.68 Million
Q3 2020 Nov 16, 2020	SELL	$10.57 - $16.0 $4.86 Million - $7.36 Million	-460,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.5 - $17.36 $4.83 Million - $7.99 Million	460,000 New	460,000 $7.4 Million
Q4 2019 Feb 14, 2020	SELL	$14.08 - $18.5 $975,377 - $1.28 Million	-69,274 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.55 - $20.52 $1.01 Million - $1.42 Million	69,274 New	69,274 $1.23 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.